- Home
- KPRX vs REBN Comparison
KPRX vs REBN Comparison
Compare KPRX & REBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- REBN
- Stock Information
- Founded
- KPRX 1998
- REBN 2015
- Country
- KPRX United States
- REBN United States
- Employees
- KPRX N/A
- REBN N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- REBN Restaurants
- Sector
- KPRX Health Care
- REBN Consumer Discretionary
- Exchange
- KPRX Nasdaq
- REBN Nasdaq
- Market Cap
- KPRX 8.3M
- REBN 13.5M
- IPO Year
- KPRX N/A
- REBN 2022
- Fundamental
- Price
- KPRX $3.20
- REBN $2.68
- Analyst Decision
- KPRX Strong Buy
- REBN
- Analyst Count
- KPRX 1
- REBN 0
- Target Price
- KPRX $10.00
- REBN N/A
- AVG Volume (30 Days)
- KPRX 9.5K
- REBN 106.3K
- Earning Date
- KPRX 05-09-2025
- REBN 03-31-2025
- Dividend Yield
- KPRX N/A
- REBN N/A
- EPS Growth
- KPRX N/A
- REBN N/A
- EPS
- KPRX 0.87
- REBN N/A
- Revenue
- KPRX $16,020,000.00
- REBN $5,928,533.00
- Revenue This Year
- KPRX N/A
- REBN $335.98
- Revenue Next Year
- KPRX N/A
- REBN N/A
- P/E Ratio
- KPRX $3.71
- REBN N/A
- Revenue Growth
- KPRX N/A
- REBN 7.63
- 52 Week Low
- KPRX $2.51
- REBN $1.03
- 52 Week High
- KPRX $5.55
- REBN $8.80
- Technical
- Relative Strength Index (RSI)
- KPRX 62.37
- REBN 31.56
- Support Level
- KPRX $3.06
- REBN $2.89
- Resistance Level
- KPRX $3.29
- REBN $3.50
- Average True Range (ATR)
- KPRX 0.20
- REBN 0.35
- MACD
- KPRX 0.08
- REBN -0.06
- Stochastic Oscillator
- KPRX 88.46
- REBN 13.02
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.